Vident Advisory’s Summit Therapeutics SMMT Stock Holding History

Vident Advisory’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,880	Closed	-$628K	–	1926
2025 Q4	$628K	Sell	35,880 -766	-2%	-$14.4K	0.01%	1032
2025 Q3	$757K	Sell	36,646 -2,510	-6%	-$60.9K	0.01%	967
2025 Q2	$833K	Sell	39,156 -2,027	-5%	-$46.2K	0.01%	809
2025 Q1	$794K	Buy	+41,183	New	+$826K	0.01%	814

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vident Advisory's SMMT Position: Q1 2026 in Review

Vident Advisory sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 35,880 shares — an estimated $628K sold.

Vident Advisory first reported a position in SMMT in Q1 2025 and held it in 4 quarters. The position peaked at $833K in Q2 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Vident Advisory reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
Vident Advisory sold 35,880 Summit Therapeutics shares in Q1 2026, an estimated $628K.
Vident Advisory first reported a position in Summit Therapeutics in Q1 2025 and held it in 4 quarters.
Vident Advisory's Summit Therapeutics position peaked at $833K in Q2 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.